Allos Therapeutics, Inc. leads Tuesday small-cap pre-market volume
Allos Therapeutics, Inc. (Nasdaq: ALTH) reported its clinical trial for Efaproxyn failed to show that the drug improved survival in women with breast cancer that spread to the brain.
EPIX Pharmaceuticals, Inc. (Nasdaq: EPIX) announced that it has received a negative response from the FDA regarding the company's appeal for immediate approval of Vasovist, a treatment used to diagnose vascular disease.
Syntax-Brillian Corp. (Nasdaq: BRLC) is launching its new 65” LCD high-definition television today.
Vical Inc. (Nasdaq: VICL) reported that preliminary late-stage trial results showed a drug candidate successfully treated the blood flow disease ischemia by increasing the size of blood vessels.
Analyst William Ho raised his rating on Acorda Therapeutics Inc. (Nasdaq: ACOR) to “buy” from “neutral.”
The following are the most actively traded companies in Tuesday pre-market trading among those with market capitalizations under $500 million:
| Price at | % | ||||||
| 9:16 et | Change | Change | Volume | Year High | Year Low | ||
| ALTH | ALLOS THERAPEUTICS INC | 5.59 | -0.02 | -0.4% | 889.9k | 8.54 | 3.23 |
| EPIX | EPIX PHARMACEUTICALS INC | 6.69 | +0.85 | +14.6% | 82.1k | 8.75 | 3.36 |
| TXCO | TXCO RES INC | 11.68 | +0.00 | +0.0% | 40.0k | 14.62 | 8.55 |
| CYBS | CYBERSOURCE CORP | 12.65 | +0.44 | +3.6% | 25.2k | 13.84 | 9.02 |
| JSDA | JONES SODA CO | 16.00 | -0.40 | -2.4% | 23.5k | 32.60 | 7.51 |
| BRLC | SYNTAX BRILLIAN CORP | 5.35 | +0.03 | +0.6% | 21.7k | 11.70 | 2.20 |
| HOKU | HOKU SCIENTIFIC INC | 7.20 | +0.10 | +1.4% | 10.3k | 7.95 | 2.12 |
| VICL | VICAL INC | 5.95 | +0.00 | +0.0% | 10.1k | 7.38 | 4.20 |
| SIFY | SIFY LTD | 8.82 | -0.13 | -1.5% | 8.3k | 10.77 | 7.31 |
| ACOR | ACORDA THERAPEUTICS INC | 19.25 | +0.81 | +4.4% | 7.0k | 26.58 | 2.20 |
About the Author
Reporter Will Atkinson is based in SmallCapInvestor.com's Washington, D.C. bureau.
Read More
(click a star)
Enter comment: